CORTICOSTEROIDS EXACERBATE OCULAR HERPES SIMPLEX

1965 ◽  
Vol 1 (9) ◽  
pp. 324-324
Keyword(s):  
Herpes Simplex ◽  
Ocular Herpes

Acyclovir in general practice

1992 ◽  
Vol 30 (26) ◽  
pp. 101-104 ◽  
Keyword(s):  
General Practice ◽  
Herpes Simplex ◽  
Early Treatment ◽  
Systemic Treatment ◽  
Systemic Infection ◽  
Herpes Viruses ◽  
Important Advance ◽  
Varicella Zoster ◽  
Ocular Herpes ◽  
The Cost

Acyclovir (Zovirax; Wellcome) is now widely prescribed for the treatment of herpes infections. In 1984 we hailed acyclovir as an important advance for the “early treatment of primary skin and ocular herpes simplex infections and for varicella-zoster infections requiring systemic treatment”, but warned against using it “indiscriminately in view of the cost, the lack of data on toxicity and the increasing number of acyclovir-resistant herpes viruses being reported.”1 In this article we appraise the place of acyclovir in general practice and so for the treatment of patients likely to be immunocompetent and without severe systemic infection.

scholarly journals Herpes simplex keratitis - an unusual clinical presentation

1970 ◽  
Vol 1 (2) ◽  
pp. 136-138
Author(s):  
SK Arya ◽  
C Malhotra ◽  
R Bhatia ◽  
S Sood
Keyword(s):  
Herpes Simplex ◽  
Anterior Chamber ◽  
Young Patient ◽  
Corneal Epithelium ◽  
Clinical Presentation ◽  
Corneal Stroma ◽  
Unusual Presentation ◽  
Ocular Herpes ◽  
Herpes Simplex Keratitis ◽  
Topical Acyclovir

A case of posterior corneal abscess with extension into the anterior chamber, in the presence of an intact corneal epithelium and clear anterior corneal stroma, occurring in a young patient is described. The patient responded to treatment with systemic and topical acyclovir. The diagnosis of presumed herpes simplex keratitis was made. We report this unusual presentation of ocular herpes manifesting as a posterior corneal and anterior chamber abscess. Keywords: ocular herpes; corneal abscess; acyclovir DOI: 10.3126/nepjoph.v1i2.3689 Nep J Oph 2009;1(2):136-138

Experimental reactivation of ocular herpes simplex in rabbits

1976 ◽  
Vol 21 (2) ◽  
pp. 185-190 ◽  
Author(s):  
Anthony B. Nesburn ◽  
Randolph Dickinson ◽  
Maria Radnoti ◽  
Mary J. Green
Keyword(s):  
Herpes Simplex ◽  
Ocular Herpes

scholarly journals Consequences of CXCL10 and IL-6 Induction by the Murine IFN-α1 Transgene in Ocular Herpes Simplex Virus Type 1 Infection

2004 ◽  
Vol 30 (2) ◽  
pp. 191-200 ◽  
Author(s):  
Stephanie Wickham ◽  
John Ash ◽  
Thomas E. Lane ◽  
Daniel J. J. Carr
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Virus Type ◽  
Herpes Simplex Virus Type ◽  
Ocular Herpes ◽  
Simplex Virus

scholarly journals Spread of Virus and Distribution of Latent Infection Following Ocular Herpes Simplex in the Non-immune and Immune Mouse

1982 ◽  
Vol 63 (1) ◽  
pp. 95-101 ◽  
Author(s):  
A. B. Tullo ◽  
C. Shimeld ◽  
W. A. Blyth ◽  
T. J. Hill ◽  
D. L. Easty
Keyword(s):  
Herpes Simplex ◽  
Latent Infection ◽  
Immune Mouse ◽  
Ocular Herpes

scholarly journals Corrigendum to “Antibody-based immunotherapy of acyclovir resistant ocular herpes simplex virus infection” [Virology 512 (2017) 194–200]

Virology ◽  
2019 ◽  
Vol 526 ◽  
pp. 231-232
Author(s):  
Dirk Bauer ◽  
Jessica Keller ◽  
Mira Alt ◽  
Axel Schubert ◽  
Ulrich Wilhelm Aufderhorst ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Virus Infection ◽  
Herpes Simplex Virus Infection ◽  
Ocular Herpes ◽  
Simplex Virus

scholarly journals Potent In Vivo Antiviral Activity of the Herpes Simplex Virus Primase-Helicase Inhibitor BAY 57-1293

2002 ◽  
Vol 46 (6) ◽  
pp. 1766-1772 ◽  
Author(s):  
Ulrich A. K. Betz ◽  
Rüdiger Fischer ◽  
Gerald Kleymann ◽  
Martin Hendrix ◽  
Helga Rübsamen-Waigmann
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Antiviral Activity ◽  
Lethal Challenge ◽  
Antiviral Compounds ◽  
Ocular Herpes ◽  
Spread Model ◽  
Simplex Virus

ABSTRACT BAY 57-1293 belongs to a new class of antiviral compounds and inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase-helicase complex. In various rodent models of HSV infection the antiviral activity of BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections. The compound shows profound antiviral activity in murine and rat lethal challenge models of disseminated herpes, in a murine zosteriform spread model of cutaneous disease, and in a murine ocular herpes model. It is active in parenteral, oral, and topical formulations. BAY 57-1293 continued to demonstrate efficacy when the onset of treatment was initiated after symptoms of herpetic disease were already apparent.

Sign in / Sign up

Export Citation Format

Share Document